Background: It was the aim to determine the effect of graft steatosis on intraoperative organ blood flow, postoperative liver function, and organ survival.
Methods: A total of 225 consecutive liver transplants were reviewed. Liver blood flow, hepatic function (AST, ALT, prothrombin time), and organ survival were determined. Donor liver grafts were categorized into 2 subgroups: mild (<30%) (n = 175) and moderate to severe (>/=30%) (n = 50) macrovesicular steatosis.
Results: Moderate to severe steatosis was associated with significantly increased AST and ALT levels and significantly diminished prothrombin time on the first and second postoperative day. By day 7 differences in liver function were no longer evident. Organ blood flow was not affected by steatosis. After adjustment for potential confounders, organ survival did not depend on the degree of donor steatosis (5-year-survival rates: 68% and 58% with steatosis <30%, or >/= 30%, respectively) (hazard ratio .754, confidence interval .458-1.242, P = .268).
Conclusion: Steatotic livers can be transplanted safely with good results for long-term organ survival if other contraindications are absent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjsurg.2007.02.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pan-cancer analysis and single-cell analysis identifies the CENPN as a biomarker for survival prognosis and immunotherapy.
Discov Oncol
January 2025
Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, China.
Background: Centromere protein N (CENPN), located on chromosome 16q23.2, encodes vital nucleosome-associated complexes that are essential for dynamic assembly processes. CENPN plays a pivotal role in regulating cell proliferation and cell cycle progression by influencing mitotic events.
View Article and Find Full Text PDFAmid a boom in organ donation, a heightened focus on cancer risk in transplant recipients: Immunosuppression, transmissible infections and tumors, and improved long-term survival among organ recipients are requiring more vigilance for skin cancers and other malignancies.
Cancer Cytopathol
February 2025
Three-dimensional genome architecture in intrahepatic cholangiocarcinoma.
Cell Oncol (Dordr)
January 2025
College of Life Science and Technology, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing, 100029, China.
Purpose: Intrahepatic cholangiocarcinoma (ICC) is a common primary hepatic tumors with a 5-year survival rate of less than 20%. Therefore, it is crucial to elucidate the molecular mechanisms of ICC. Recently, the advance of high-throughput chromosome conformation capture (Hi-C) technology help us look insight into the three-dimensional (3D) genome structure variation during tumorigenesis.
View Article and Find Full Text PDFA melanoma brain metastasis CTC signature and CTC:B cell clusters associate with secondary liver metastasis: a melanoma brain-liver metastasis axis.
Cancer Res Commun
January 2025
University of New Mexico, Albuquerque, NM, United States.
Melanoma brain metastasis (MBM) is linked to dismal prognosis, low overall survival, and is detected in up to 80% of patients at autopsy. Circulating tumor cells (CTCs) are the smallest functional units of cancer and precursors of fatal metastasis. We previously employed an unbiased multilevel approach to discover a unique ribosomal protein large/small subunits (RPL/RPS) CTC gene signature associated with MBM.
View Article and Find Full Text PDFFriend or Foe? Safety and Efficacy of Hepatitis B Viremic Solid Organ Allograft into Seronegative Recipients.
J Am Coll Surg
January 2025
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group. Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Background: Long-term outcomes of HBV nucleic acid test (NAT)-positive (+) allograft use in seronegative liver transplant (LT) and kidney transplant (KT) recipients remains unknown despite being incorporated into practice by select centers. This study compares long-term outcomes between HBV NAT+ and NAT-negative (-) allografts in seronegative recipients.
Study Design: All recipients of an HBV core antibody-positive (HBcAb+) LT or KT were prospectively evaluated at a single transplant center from 6/2015-3/2023 and compared by NAT status.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!